Program
pirtobrutinib
Also written as “Pirtobrutinib”, “LOXO-305” and “[14C]-LOXO-305”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Mantle-Cell · Renal Insufficiency, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 2811 open or running | phase 4since Mar 6, 2025 | Nov 6, 2018 | Oct 2027phase 3 · NCT05254743 |
| AstraZeneca | 10 open or running | phase 2since Jan 21, 2025 | Jan 21, 2025 | none ahead |
| Nurix Therapeutics | 11 open or running | phase 3since Mar 31, 2026 | Mar 31, 2026 | Oct 2029phase 3 · NCT07516093 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Nov 6, 2018.
- Oct 22, 20212 phase 1 studies in Healthy VolunteersEli Lilly · NCT05134350, NCT05134337
- Jan 3, 2022Phase 1 study in HealthyEli Lilly · NCT05176314 · 32 enrolled · United States
- Feb 15, 2022Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT05254743 · 737 planned · United States, Argentina, Australia and more
- Oct 24, 2023Phase 2 study in Multiple SclerosisEli Lilly · NCT06104683 · United States, Puerto Rico
- Nov 30, 2023Phase 1 study in HealthyEli Lilly · NCT06165146 · 16 enrolled · United States
- Dec 11, 20239 phase 1 studiesEli Lilly · NCT06190691, NCT06190678, NCT06194214 and 6 more
- Feb 6, 2024Phase 1 study in HealthyEli Lilly · NCT06258174 · 28 enrolled · United States
- Sep 6, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06588478 · 249 planned · United States, Australia, Belgium and more
- Dec 3, 2024Phase 2 study in Purpura, Thrombocytopenic, IdiopathicEli Lilly · NCT06721013 · 68 planned · United States, China, Denmark and more
- Jan 21, 2025AstraZeneca’s first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AstraZenecaAstraZeneca · NCT06839872
- Mar 6, 20252 phase 4 studies in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06876662, NCT06876649
- Aug 29, 2025Phase 2 study in Lymphoma, Non-HodgkinEli Lilly · NCT07162181 · 13 enrolled · China
- Oct 16, 2025Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT07218341 · 150 planned · United States, Australia, Austria and more
- Mar 31, 2026Nurix Therapeutics’ first study: phase 3 study in Lymphoma, B-CellNew to Nurix TherapeuticsNurix Therapeutics · NCT07516093 · 620 planned · United States
Ahead
- Oct 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT05254743
- Nov 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellEli Lilly · NCT04662255
- Feb 2028Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicEli Lilly · NCT06721013
- Jun 2028Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellEli Lilly · NCT06588478
TargetBeta
“An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07516093Lymphoma, B-Cell · United States | 3 | Recruiting | Nurix Therapeutics | Oct 2029 | 620 |
| NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 4 | Recruiting | Eli Lilly | May 2030 | 150 |
| NCT07162181Lymphoma, Non-Hodgkin · China | 2 | Active, not recruiting | Eli Lilly | May 2030 | 13 |
| NCT06876662Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 4 | Recruiting | Eli Lilly | May 2030 | 279 |
| NCT06876649Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 4 | Recruiting | Eli Lilly | May 2030 | 787 |
| NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | AstraZeneca | Jul 28, 2028 | 0 |
| NCT06721013Purpura, Thrombocytopenic, Idiopathic · United States, China, Denmark and more | 2 | Recruiting | Eli Lilly | Feb 2028 | 68 |
| NCT06588478Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | Jun 2028 | 249 |
| NCT06258174Healthy · United States | 1 | Completed | Eli Lilly | Dec 22, 2021 | 28 |
| NCT06215521Healthy · United States | 1 | Completed | Eli Lilly | Mar 31, 2021 | 31 |
| NCT06215430Healthy · United States | 1 | Completed | Eli Lilly | Apr 15, 2021 | 16 |
| NCT06194214Healthy · United States | 1 | Completed | Eli Lilly | Jun 9, 2021 | 16 |
| NCT06181006Healthy · United States | 1 | Completed | Eli Lilly | Dec 1, 2020 | 24 |
| NCT06180980Healthy · United States | 1 | Completed | Eli Lilly | Mar 8, 2021 | 20 |
| NCT06180967Healthy · United States | 1 | Completed | Eli Lilly | Oct 20, 2020 | 15 |
| NCT06180954Healthy · United States | 1 | Completed | Eli Lilly | Nov 6, 2020 | 9 |
| NCT06190691Hepatic Insufficiency · United States | 1 | Completed | Eli Lilly | Dec 30, 2021 | 36 |
| NCT06190678Renal Insufficiency · United States | 1 | Completed | Eli Lilly | Jun 4, 2021 | 16 |
| NCT06165146Healthy · United States | 1 | Completed | Eli Lilly | Dec 30, 2020 | 16 |
| NCT06104683Multiple Sclerosis · United States, Puerto Rico | 2 | Withdrawn | Eli Lilly | Jan 16, 2026 | 0 |
| NCT05254743Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Oct 2027 | 737 |
| NCT05176314Healthy · United States | 1 | Completed | Eli Lilly | Apr 20, 2022 | 32 |
| NCT05134350Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Mar 23, 2020 | 10 |
| NCT05134337Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Oct 30, 2020 | 27 |
| NCT05023980Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Eli Lilly | Jul 11, 2025 | 282 |
| NCT04965493Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Active, not recruiting | Eli Lilly | Oct 2026 | 600 |
| NCT04849416Leukemia, Lymphoid · China | 2 | Completed | Eli Lilly | Apr 10, 2023 | 87 |
| NCT04666038Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Eli Lilly | Aug 29, 2023 | 238 |
| NCT04662255Lymphoma, Mantle-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Eli Lilly | Nov 2027 | 500 |
| NCT03740529Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 2 | Completed | Eli Lilly | Jan 27, 2025 | 803 |
How it is read
Names in the registry
- “Pirtobrutinib”, 26 entries
- “LOXO-305”, 3 entries
- “[14C]-LOXO-305”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 11 studies
- Lymphoma, B-Cell, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lymphoma, Mantle-Cell, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.